Literature DB >> 6549015

Detection of protein C activation in humans.

K A Bauer, B L Kass, D L Beeler, R D Rosenberg.   

Abstract

We have developed a radioimmunoassay (RIA) for the dodecapeptide that is liberated from protein C when this zymogen is activated by thrombin bound to thrombomodulin present on the vascular endothelium. The protein C activation peptide (PCP) was synthesized using the solid-phase method of Merrifield. Antisera were raised in rabbits to the synthetic analogue coupled to bovine serum albumin with glutaraldehyde. The antibody population obtained was used together with a 125I-labeled tyrosinated ligand and various concentrations of unlabeled PCP to construct a double antibody RIA capable of measuring as little as 10 pM of this component. We have established that the synthetic dodecapeptide has the same immunoreactivity as the native peptide and that the reactivity of protein C is less than 1/2,000 that of PCP on a molar basis. The extremely low levels of peptide in normal individuals as well as the nonspecific contributions of plasma constituents to the immunoreactive signal, necessitated the development of a procedure by which the PCP could be reproducibly extracted from plasma and concentrated approximately 20-fold. This methodology permitted us to demonstrate that the plasma PCP levels in 17 normal donors averaged 6.47 pM, and that elevations up to 180 pM were observed in individuals with evidence of disseminated intravascular coagulation. The validity of these measurements of protein C activation is supported by the fact that, in both of these situations, the RIA signal migrates on reverse-phase high pressure liquid chromatography in a manner identical to that of the native dodecapeptide. We have also noted that the mean PCP concentration in seven patients fully anticoagulated with warfarin averaged 2.61 pM. Our studies also show that PCP is cleared from the plasma of primates with a t1/2 of approximately 5 min. Given that the t1/2 of activated protein C is estimated to be 10-15 min, the latter enzyme appears to exert its effects on the activated cofactors of the coagulation system at concentrations considerably less than 1.0 nM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6549015      PMCID: PMC425392          DOI: 10.1172/JCI111626

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

Review 2.  Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays.

Authors:  D Rodbard
Journal:  Clin Chem       Date:  1974-10       Impact factor: 8.327

Review 3.  Solid-phase peptide synthesis.

Authors:  R B Merrifield
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1969

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Multiple bovine thrombin components.

Authors:  R D Rosenberg; D F Waugh
Journal:  J Biol Chem       Date:  1970-10-10       Impact factor: 5.157

6.  The defibrination syndrome: clinical features and laboratory diagnosis.

Authors:  C Merskey; A J Johnson; G J Kleiner; H Wohl
Journal:  Br J Haematol       Date:  1967-07       Impact factor: 6.998

7.  Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin.

Authors:  J S Rosenberg; D L Beeler; R D Rosenberg
Journal:  J Biol Chem       Date:  1975-03-10       Impact factor: 5.157

8.  ANTIBODIES TO BRADYKININ AND ANGIOTENSIN: A USE OF CARBODIIMIDES IN IMMUNOLOGY.

Authors:  T L GOODFRIEND; L LEVINE; G D FASMAN
Journal:  Science       Date:  1964-06-12       Impact factor: 47.728

9.  Solid-phase synthesis of (2-isoleucine, 4-leucine) oxytocin and (2-phenylalanine, 4-leucine) oxytocin and some their pharmacological properties.

Authors:  V J Hruby; F Muscio; C M Gronginsky; P M Gitu; D Saba; W Y Chan
Journal:  J Med Chem       Date:  1973-06       Impact factor: 7.446

10.  Measurement of fibrinopeptide A in human blood.

Authors:  H L Nossel; I Yudelman; R E Canfield; V P Butler; K Spanondis; G D Wilner; G D Qureshi
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  11 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  The importance of the endothelium in atherothrombosis and coronary stenting.

Authors:  Fumiyuki Otsuka; Aloke V Finn; Saami K Yazdani; Masataka Nakano; Frank D Kolodgie; Renu Virmani
Journal:  Nat Rev Cardiol       Date:  2012-05-22       Impact factor: 32.419

Review 3.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

4.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

5.  Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.

Authors:  S Vigano D'Angelo; P C Comp; C T Esmon; A D'Angelo
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

6.  Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids. Enhancement by sulphated polysaccharides.

Authors:  J M Freyssinet; M L Wiesel; L Grunebaum; J M Pereillo; J Gauchy; S Schuhler; G Freund; J P Cazenave
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

7.  Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism.

Authors:  John-Bjarne Hansen; José A Fernández; Knut H Borch; John H Griffin; Jan H Brox; Sigrid K Braekkan
Journal:  Thromb Res       Date:  2011-07-20       Impact factor: 3.944

8.  Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

9.  Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.

Authors:  E M Conway; K A Bauer; S Barzegar; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

10.  [The clinical importance of protein C and S deficiency for surgical patients].

Authors:  H Rabl; H Fruhwirth
Journal:  Langenbecks Arch Chir       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.